Navigation Links
Global H1N1 Vaccines Market to Reach US $273 Million by 2018, According to a New Report by Global Industry Analysts, Inc.
Date:8/14/2013

San Jose, California (PRWEB) August 14, 2013

Follow us on LinkedIn – Worldwide influenza vaccine sales skyrocketed in the year 2009 with the introduction of vaccines to tackle the Influenza A (H1N1) pandemic virus. However, the momentum provided by the dreaded Swine Flu, ran out of steam by August 2010, with the World Health Organization (WHO) officially declaring the disease to have entered the post-pandemic stage. Nevertheless, the WHO continues to monitor outbreaks and prevalence of the H1N1 flu virus. Small outbreaks in Influenza A (H1N1)pdm09 virus were reported in certain countries of Asia, Africa, Europe, South America, as well as Central America in the post-pandemic phase. The Influenza A (H1N1)pdm09 virus is considered responsible for all the seasonal activity of (H1N1) A viruses between September 2012 and January 2013.

As a precautionary measure, WHO recommends manufacturers to include strain of A/California/7/2009 (H1N1)pdm09-like virus in the formulation of in-house seasonal influenza vaccines. Based on the WHO advisory, several governments across the globe continue to stock up on monovalent H1N1 vaccines to prevent another outbreak of the disease, besides immunizing the general population with trivalent and quadrivalent seasonal influenza vaccines, containing the analogous strain of the 2009 H1N1 virus in accordance with the availability and affordability of the vaccines in each geographic region.

The recent advancements in cell-culture and recombinant technologies are boosting the speed and efficiency of the vaccine production processes. However, the traditional egg-based production method remains the most widely used method for vaccine preparation. This method however requires larger time-frames and thereby result in inadequate supply of the necessary vaccines in case of a sudden pandemic attack. New strains of viruses resulting from antigenic shift of the A/California/7/2009 (H1N1)pdm09 virus, usually occurring when the virus is being passed on from animal to animal or a human being, also stresses the need to develop more effective vaccines. However, manufacturers face a daunting challenge in the form of the huge costs involved in vaccine development, clinical trials, regulatory approval, mass production, and commercialization.

North America accounts for the largest share of H1N1 vaccine sales worldwide, as stated by the new market research report on H1N1 Vaccines. Rapid growth in birth cohorts in developing countries, coupled with the improvement in access to public and private healthcare and increased spending, entail a growing demand for vaccines in the developing world. Notably, the 2009 H1N1 pandemic resulted in widespread panic in China and India, partly due to the respective government’s unpreparedness to handle the disease outbreak. The governments in these countries are expected to continue domestic production and stockpiling of reserve H1N1 vaccine doses in the near term. Increasing public awareness about influenza vaccines, coupled with the need to safeguard the population in the event of a future outbreak, will continue to drive sales of H1N1 vaccines.

Key players covered in the report include Baxter International Inc., CPL Biologicals Pvt. Ltd., CSL Limited, bioCSL, GlaxoSmithKline Plc., MedImmune LLC, Novartis AG, Sanofi Pasteur SA, Sinovac Biotech Ltd., and Zydus Cadilla.

The research report titled “H1N1 Vaccines: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides an in-depth study of the key factors influencing the performance of H1N1 influenza vaccines market, pertinent macro and micro market trends, key growth drivers and inhibitors, and recent strategic corporate initiative. The report also provides revenue estimates and forecasts for H1N1 vaccines in US$ million for the four major geographic regions including North America, Europe, Asia-Pacific, and Rest of World.

For more details about this comprehensive market research report, please visit – http://www.strategyr.com/H1N1_Vaccines_Market_Report.asp

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.

Follow us on LinkedIn

Global Industry Analysts, Inc.
Telephone: 408-528-9966
Fax: 408-528-9977
Email: press(at)StrategyR(dot)com
Web Site: http://www.StrategyR.com/

###

Read the full story at http://www.prweb.com/releases/H1N1_vaccines_market/swine_flu_virus/prweb11026598.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. ResearchMoz.us: RFID Blood Monitoring Systems (Blood Refrigerators and Freezers) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
2. Global Adhesives and Sealants Market 2012-2016 - Worldwide Industry Growth, Opportunity, Players, Size And Forecast Research Report Available Online
3. Global Lung Cancer Therapeutics Market 2013 Report Featuring Leading Players Such As AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Co., GlaxoSmithKline, Hoffmann-La Roche, Novartis And Others
4. The Global Next Generation Sequencing (NGS) Market is Poised to Reach $2.7 Billion by 2017 Says Latest Report
5. The Global Surgical Equipment Market to Grow At A CAGR Of 6.25 Percent over the Period 2012-2016
6. Global Crop Protection Chemicals Market Till 2016 - Worldwide Research Report, Industry Share, Size, Trends, Analysis, Growth and Forecast 2012-2016: MarketResearchReports
7. Environmental Concerns & Depleting Fossil Fuels Drive the Global Renewable Chemicals Market, According to New Report by Global Industry Analysts, Inc.
8. Cell Culture Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018
9. In Vitro Diagnostics Market is Expected to Reach USD 74.2 Billion Globally in 2018: Transparency Market Research
10. Pain Management Therapeutics Market is Expected to Decline to USD 29.47 Billion Globally by 2018: Transparency Market Research
11. RFID Blood Monitoring Systems (Blood Refrigerators and Freezers) Market is Expected to Reach USD 174.2 Million Globally in 2019: Transparency Market Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... 22, 2017 , ... ProMIS Neurosciences (“ProMIS” or the “Company”), ... today announced it has issued a scientific white paper entitled “Results from recent ... of commentaries from ProMIS’s scientific team offering insight into the Company’s product portfolio ...
(Date:2/22/2017)... Feb. 22, 2017 Origin (Origin Agritech, LLC, a subsidiary ... seed provider, and Arcadia (Arcadia Biosciences, Inc., ... and commercializes agricultural productivity traits and nutritional products, today announced their ... product developed in China to ... ...
(Date:2/22/2017)... SAN DIEGO , Feb. 22, 2017 ... announced today expansion of its translational research program ... through establishment of laboratory facilities in San Diego.  ... San Diego BioLabs facility, a biotechnology incubator sponsored ... Sanofi. In November 2016, the Company ...
(Date:2/21/2017)... ... 2017 , ... During HIMSS 2017, CloudMine, a secure, cloud-based ... partnership with Redox, a leader in cloud-based healthcare integration and API services. The ... data secure in the cloud. , The digital health developers, and various healthcare ...
Breaking Biology Technology:
(Date:2/8/2017)... 7, 2017 Report Highlights ... The global synthetic-biology market reached ... by 2021, growing at a compound annual growth rate (CAGR) ... of the global markets for synthetic biology. - Analyses of ... and projections of compound annual growth rates (CAGRs) through 2021. ...
(Date:2/7/2017)... 7, 2017   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that the ... innovative, highly flexible and award winning eClinical solution, is ... iMedNet is a proven Software-as-a-Service (SaaS) clinical research ... (EDC), but also delivers an entire suite of eClinical ...
(Date:2/6/2017)... , Feb. 6, 2017 According to ... are driving border authorities to continue to embrace ... there are 2143 Automated Border Control (ABC) eGates ... deployed at more than 163 ports of entry ... to 2016 achieving a combined CAGR of 37%. ...
Breaking Biology News(10 mins):